March 31^st, 2025

Enantia is pleased to announce the acquisition of the Empyrean X-ray diffractometer by Malvern Panalytical, further strengthening our solid-state analysis capabilities. This state-of-the-art instrument enhances our ability to characterize and analyze polymorphs, cocrystals and salts, with the highest sensitivity, reinforcing our expertise in solid-state screening and development.

The Empyrean X-ray diffractometer is a versatile and high-performance system, enabling advanced characterization of drug substances and drug products at various stages of drug development.

Its cutting-edge technology allows for detailed structural analysis in solid form development, crystallization process optimization, and intellectual property strategy.

In addition to the Empyrean, Enantia also operates the Aeris X-ray diffractometer (fully dedicated to High Potent APIs), further expanding our capabilities in solid-state characterization.